Antibody-drug conjugates in colorectal cancer: current landscape and future perspectives from clinical trials

Background Advanced colorectal cancer (CRC) has limited therapeutic options. Antibody-drug conjugates (ADCs) deliver cytotoxic agents selectively, minimizing systemic toxicity. This study outlines the current clinical trial landscape of ADCs in CRC to identify research gaps and future directions. Methods We queried the Trialtrove database (up to August 2025) for non-observational trials of ADCs in CRC. Analytical indicators included temporal trends, geographic distribution, sponsor type, target